---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-032463"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:17:13.609344+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reviva raises $30M in registered direct offering of common stock and warrants

## Summary
- Offering of 5,853,660 shares (or pre-funded warrants) and 5,853,660 warrants at $5.125 per unit.
- Warrants exercisable at $5.00 per share, expire 5 years from issuance.
- Net proceeds expected ~$27.9M; director affiliate purchased $3M in pre-funded warrants.
- Proceeds to fund registrational Phase 3 RECOVER-2 trial and other R&D activities.
- Closing expected on or about November 20, 2023, subject to customary conditions.

## SEC filing metadata
- accession: 0001437749-23-032463
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923032463/0001437749-23-032463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923032463/rvph20231115_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-032463
- JSON: https://secwatch.observer/filing/0001437749-23-032463.json
- Plain text: https://secwatch.observer/filing/0001437749-23-032463.txt

## Key facts
- Material Agreements
  REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Securities Purchase Agreement with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors valued at approximately $27.9 million (effective 2023-11-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors
  - Value: approximately $27.9 million
  - Effective: 2023-11-15
  source text: On November 15, 2023, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors (the “Director Affiliate” and collectively, the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers, in a registered direct offering (the “Offering”) priced at the market under Nasdaq rules, an aggregate of (i) 5,268,294 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of up to 585,366 shares of Common Stock, and (iii) warrants (the “Warrants”) exercisable for an aggregate of up to 5,853,660 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923032463/0001437749-23-032463-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.